Company news
Rallybio Corporation (NASDAQ:RLYB) news
Rallybio Corporation news releases on 6ix. Latest, Jun 2, 2026: Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation…
Press releases & updates
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
June 2, 2026
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
May 31, 2026
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
March 1, 2026
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
February 17, 2026
Rallybio Announces Reverse Stock Split of Common Stock
February 3, 2026
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 6, 2025
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic, Pharmacodynamic Study
September 26, 2025
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
September 25, 2025
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
September 3, 2025
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 7, 2025
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
July 8, 2025
ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
July 7, 2025
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study
June 13, 2025
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
June 12, 2025
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
May 8, 2025
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
April 29, 2025
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
April 8, 2025
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
March 13, 2025
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
February 25, 2025
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
February 10, 2025
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
January 9, 2025
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
December 9, 2024
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
December 1, 2024
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
November 26, 2024
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
November 24, 2024
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
November 20, 2024
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 6, 2024
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
October 28, 2024
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
September 22, 2024
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
September 9, 2024
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
September 8, 2024
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
August 28, 2024
Rallybio to Present at Upcoming Investor Conferences
August 26, 2024
Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 7, 2024
Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
July 8, 2024
Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
June 16, 2024
Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates
May 8, 2024
Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference
May 6, 2024
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
April 16, 2024
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
April 9, 2024
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting
March 31, 2024
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
February 25, 2024
Rallybio Announces Portfolio Prioritization and Provides Corporate Update
February 5, 2024
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024
January 3, 2024
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
December 19, 2023
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
December 8, 2023
Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
November 27, 2023
Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 8, 2023
Rallybio to Present at Upcoming Investor Conferences in November
November 7, 2023